Drug development and potential targets for Cushing's syndrome

Eur J Med Chem. 2024 Mar 22;270:116333. doi: 10.1016/j.ejmech.2024.116333. Online ahead of print.ABSTRACTCushing's syndrome (CS) is a complex disorder characterized by the excessive secretion of cortisol, with Cushing's disease (CD), particularly associated with pituitary tumors, exhibiting heightened morbidity and mortality. Although transsphenoidal pituitary surgery (TSS) stands as the primary treatment for CD, there is a crucial need to optimize patient prognosis. Current medical therapy serves as an adjunctive measure due to its unsatisfactory efficacy and unpredictable side effects. In this comprehensive review, we delve into recent advances in understanding the pathogenesis of CS and explore therapeutic options by conducting a critical analysis of potential drug targets and candidates. Additionally, we provide an overview of the design strategy employed in previously reported candidates, along with a summary of structure-activity relationship (SAR) analyses and their biological efficacy. This review aims to contribute valuable insights to the evolving landscape of CS research, shedding light on potential avenues for therapeutic development.PMID:38569434 | DOI:10.1016/j.ejmech.2024.116333
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Source Type: research